Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Sanofi,Alirocumab,"Heterozygous familial hypercholesterolaemia (HeFH), prevention of CV events",Alirocumab,,Community and Hospital,Cardiovascular System
